Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $2.06B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 3.26M
Average 2.47M
Returns on capital
Biohaven Ltd. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1418.8%
avg 442.2%
ROIC
-218.4%
avg -125.7%
ROA
-163.7%
avg -97.5%
Analysis
ROA is currently the strongest return metric at -163.7% versus its period average of -97.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Vladimir Coric | Chairman & Chief Executive Officer | USD 1.4M | 55 | — | — |
Matthew Buten | Chief Financial Officer | USD 858.61K | 65 | 175.00K | 0.17% |
Bruce D. Car DACVP | Chief Innovation Officer | USD 801.36K | 64 | — | — |
Kimberly Gentile | Senior Vice President of Clinical Operations | USD 757.72K | 60 | 1.00K | <0.01% |
Warren Volles | General Counsel & Chief Legal Officer | — | — | — | — |
Clifford Bechtold | President, GM of Biohaven Ireland & Chief Compliance Officer | — | — | — | — |
George C. Clark | Vice President & Chief Accounting Officer | — | 41 | 50.00K | 0.05% |
John McGill | Chief Technology Officer | — | — | — | — |
Deb Young | Senior Director of Regulatory Affairs & Operations | — | — | — | — |
Jennifer Porcelli | Vice President of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A12 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Biohaven Ltd. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BHVN's management, answered from reported figures.
Who manages BHVN?
Biohaven Ltd. (BHVN) lists 10 active executives. The top listed executive is Bruce D. Car DACVP, Chief Innovation Officer.
Are BHVN insiders buying or selling?
Recent insider activity shows net buying of $287.01M.
Continue the stock analysis
Jump to another research area for this company.